Examining the drug rimonabant (brand name Acomplia) developed reasonable, latest published reports show that rimonabant sustained weight loss and blood markers after two years, according to an article published in the February 15 of the Journal of the American Medical Association.

Besides losing weight, study participants taking rimonabant also demonstrated high-density lipoprotein (HDL) cholesterol and triglycerides improved test scores over the two years.

Approximately two thirds of Americans overweight, according to authors F Xavier Pi-Sunyer, MD, of the Obesity Research Center, St Luke’s-Roosevelt Hospital, New York, and his colleagues. The extra weight strong deformities, the risk of diabetes and cardiovascular disease and death from related parties, which researchers believe this causes.Based, obesity management should not only weight loss goals (particularly around the waist only) but also improve the cardio-metabolic risk factors, such as abnormal cholesterol and blood sugar varieties.

Clinical Trial
In a randomized, double-blind, placebo run-examination, Dr. Pi-Sunyer and colleagues reviewed research drug, rimonabant, the efficacy and safety when given with food and work. Study end points reduce body weight and waist circumference, long-term weight maintenance and reduction of cardiometabolic risk factors in overweight and obese patients with the higher risk.

The analyzation was conducted from August 2001 until April 2004 and 3045 participants in obese adults (body mass index or BMI = 30 or higher) or obese (BMI>) 27 plus hypertension or dyslipidemia.

The patients were randomized to receive either rimonabant (5 mg / day), rimonabant (20 mg / day) or placebo for one years. Currently patients who were randomized to rimonabant again receive placebo or to maintain the same dose of rimonabant in the placebo group was compared with placebo in two years.

Sum of the first years of the study were:

51% of participants receiving rimonabant (5 mg / day)
55% of participants receiving rimonabant (20 mg / day)
51% of participants receiving placebo.
After one years, the participants one dose of rimonabant had significantly better weight loss than participants receiving the placebo. Currently, the proportion of participants who had at least 5% weight reduction:

26.1% of patients treated with rimonabant (5 mg / day)
48.6% of patients receiving rimonabant (20 mg / day)
20.0% in patients receiving placebo.
Participants receiving rimonabant (20 mg / day) had a greater average reduction in weight, waist circumference and triglycerides, and a better growth of the HDL-cholesterol.

The participants experienced due to the higher dose of rimonabant to placebo during the third year to gain weight, while those receiving 20 mg / day forever changed both their last sustained weight loss and cardiometabolic risk factors.

Rimonabant was generally well tolerated and the most common) with drug-related adverse events, nausea (11.2% of participants with rimonabant (20 mg / day) compared to 5.8% in the placebo group.

“It should be noted that the trials were limited by high dropout rates, and long-term impact of the demand for drugs investigated further. But our observations together and show that rimonabant is an innovative approach to managing multiple factors cardiometabolic to help them and so keep the weight-dependent and-independent pathways, “concluded the researchers.